protein
epitop
mimet
pem
rapidli
gain
promin
sourc
novel
lead
drug
vaccin
research
pem
design
mimic
threedimension
surfac
region
peptid
protein
recogn
biolog
receptor
consider
effort
focus
alreadi
design
pem
potenti
inhibitor
acid
interact
howev
excit
opportun
also
aris
use
pem
structurebas
design
synthet
vaccin
target
wide
rang
infecti
diseas
chronic
human
health
problem
allergi
alzheim
cancer
research
epitop
mimet
driven
forward
past
decad
progress
highthroughput
genom
proteom
well
massiv
growth
structur
databas
biolog
macromolecul
complex
form
exemplifi
rapid
recent
growth
number
crystal
structur
antibodi
fragment
deriv
antibodi
protect
infect
invad
pathogen
bound
pathogenderiv
antigen
vide
infra
know
structur
level
antibodi
recogn
protect
epitop
pathogen
herald
new
era
structur
vaccinolog
inform
exploit
ration
structurebas
approach
vaccin
design
nevertheless
still
remain
consider
scientif
challeng
transform
structur
inform
ration
design
molecul
desir
chemic
biolog
properti
crystal
structur
may
reveal
surfac
shape
complementar
interfac
energet
origin
bind
affin
specif
part
problem
lie
identifi
energet
import
interact
influenc
stabil
complex
import
advanc
came
identif
mani
interfac
select
group
hotspot
residu
typic
make
disproportion
larg
contribut
bind
energi
easili
identifi
alaninescan
mutagenesi
hot
residu
often
cluster
surfac
center
interfac
typic
constitut
less
half
contact
surfac
often
surround
surfac
residu
appear
contribut
rel
littl
bind
energi
surprisingli
hot
spot
becom
major
focu
interest
interact
inhibitor
design
doublemut
cycl
analys
reveal
recent
mani
interfac
appear
built
modular
fashion
cluster
residu
side
involv
network
strong
intraclust
interact
weak
interclust
connect
within
small
group
test
protein
complex
size
extent
cooper
interact
within
network
cluster
rather
surfac
area
interfac
per
se
seem
correl
higher
bind
affin
studi
reveal
higher
network
organ
interact
occur
protein
interfac
well
interact
may
import
account
ligand
bind
affin
specif
final
relationship
protein
structur
intern
dynam
also
import
ligand
bind
although
protein
intern
dynam
poorli
remain
uncharacter
new
result
suggest
fast
slower
intern
dynam
influenc
ligand
bind
way
difficult
predict
protein
ground
state
structur
collect
insight
suggest
limit
knobsintohol
approach
base
upon
maxim
surfac
complementar
commonli
taken
design
studi
much
work
review
focus
upon
design
mimet
base
motif
seen
protein
crystal
structur
motif
often
found
protein
mediat
acid
interact
compris
two
consecut
hydrogenbond
antiparallel
connect
loop
sequenc
mani
variat
observ
backbon
conform
loop
fold
protein
depend
upon
hydrogen
bond
hb
pattern
two
antiparallel
loop
length
review
see
structur
divers
captur
least
extent
mimet
design
transplant
hairpin
loop
protein
known
structur
onto
semirigid
hairpinstabil
templat
afford
macrocycl
conform
constrain
templatebound
mimet
posit
backbon
cycliz
conform
bia
impos
constrain
templat
influenc
hairpin
loop
length
sequenc
influenc
conform
stabil
fold
structur
one
conveni
templat
use
dipeptid
dpro
lpro
known
adopt
stabl
type
incorpor
cyclic
peptid
mimet
templat
nucleat
conform
possess
prefer
righthand
twist
typic
observ
adjac
antiparallel
protein
earli
exampl
approach
design
hairpin
mimet
base
upon
complementaritydetermin
region
cdr
loop
antigenbind
site
antibodi
figur
excel
structur
mimicri
observ
sever
cyclic
hairpin
mimet
correspond
cdr
loop
antibodi
fab
fragment
design
mimet
import
recogn
pair
crossstrand
residu
opposit
exist
hb
nonhb
nhb
posit
side
chain
point
differ
side
hairpin
loop
transplant
known
protein
structur
onto
dpro
lpro
templat
must
insert
nhb
posit
ntermin
ctermin
loop
residu
forc
hb
posit
ensu
hb
pattern
maintain
along
hairpin
figur
lengthen
loop
insert
one
residu
cterminu
caus
residu
hb
posit
along
strand
move
nhb
posit
vice
versa
thu
alter
distribut
side
chain
two
side
hairpin
dramat
effect
observ
seri
mimet
base
upon
loop
envelop
glycoprotein
discuss
detail
follow
templat
therefor
stabil
hairpin
backbon
conform
fix
hairpin
regist
anoth
mimet
base
upon
disulfidebond
phage
display
peptid
bind
fc
region
antibodi
crystal
structur
phage
peptid
bound
fc
protein
reveal
one
occur
two
residu
one
strand
lie
opposit
singl
residu
strand
affect
direction
backbon
also
dramat
orient
side
chain
respect
plane
featur
also
observ
mimet
deriv
phage
display
peptid
figur
place
side
chain
two
consecut
residu
onto
side
hairpin
interact
surfac
target
fc
protein
protein
known
structur
loop
residu
two
residu
hairpin
loop
type
strongli
favor
type
type
ii
type
observ
tip
mimet
deriv
initi
tat
protein
bind
nucleic
acid
target
transactiv
respons
element
tar
rna
mimet
found
adopt
stabl
structur
free
solut
bound
major
groov
tar
rna
hairpin
figur
complex
side
chain
side
peptid
hairpin
seen
make
intim
contact
rna
involv
hydrophob
polar
electrostat
interact
tip
may
also
contain
larger
loop
greater
propens
occurr
cispeptid
bond
observ
fourresidu
fiveresidu
loop
involv
xaapro
peptid
bond
type
vi
cispeptid
bond
observ
famili
mimet
deriv
sunflow
seed
trypsin
inhibitor
figur
exampl
cyclic
mimet
shown
adopt
stabl
backbon
hairpin
fold
fiveresidu
loop
stabl
ci
peptid
bond
tip
hairpin
mimet
also
potent
trypsin
inhibitor
attract
featur
mimet
eas
synthesi
typic
linear
precursor
assembl
solidphas
peptid
chemistri
cycliz
solut
deprotect
assembl
process
robust
amen
parallel
synthesi
method
allow
product
small
librari
hairpin
mimet
exampl
contain
sequenc
variat
proteinogen
nonproteinogen
amino
acid
well
array
relat
build
block
use
synthesi
mean
tailor
optim
structur
biolog
properti
mimet
way
famili
peptid
mimic
epitop
protein
bind
high
affin
interact
partner
protein
figur
identifi
exampl
famili
mimet
bind
high
affin
specif
chemokin
receptor
figur
discov
yet
anoth
found
bind
inhibit
bacteri
outer
membran
om
protein
lptd
discuss
detail
later
mimet
therefor
base
upon
fold
motif
found
natur
occur
peptid
protein
appear
repres
interest
sourc
novel
ligand
obviou
potenti
applic
drug
vaccin
research
interest
natur
occur
peptid
found
within
larg
famili
cation
antimicrobi
peptid
cap
play
import
role
innat
immun
mani
differ
organ
cap
produc
vertebr
includ
human
often
provid
first
line
defens
bacteri
viral
infect
typic
display
fascin
complex
spectrum
biolog
activ
mani
show
broadspectrum
antimicrobi
activ
gramposit
gramneg
bacteria
well
antivir
activ
addit
mani
known
exert
complex
immunomodulatori
effect
anim
mechan
still
rather
poorli
character
surprisingli
therefor
cap
becom
hot
target
peptidomimet
research
mani
cap
kill
bacteri
cell
micromolar
rang
mechan
culmin
disrupt
bacteri
cell
membran
cation
peptid
first
attract
electrostat
outer
bacteri
cell
surfac
presenc
excess
neg
charg
phospholipid
glycolipid
invad
disrupt
membran
bilay
eventu
caus
cell
lysi
process
captur
recent
seri
timeresolv
quantit
microscopi
imag
human
cathelicidin
attack
escherichia
coli
cell
howev
cap
also
lyse
typic
higher
concentr
mammalian
cell
membran
potenti
sourc
toxic
one
factor
far
prevent
applic
treatment
system
human
bacteri
infect
hand
cap
clearli
differ
mechan
action
involv
membran
lysi
recent
review
see
although
divers
array
differ
fold
secondari
structur
found
among
cap
one
group
possess
structur
stabil
disulfid
bridg
includ
protegrin
polyphemusin
tachyplesin
arenicin
one
approach
mimic
cap
exploit
properti
hairpinstabil
templat
gener
macrocycl
pem
fold
structur
figur
mimet
may
contain
sequenc
relat
cap
without
reli
presenc
constrain
disulfid
bridg
fold
structur
mimicri
coupl
eas
synthesi
therefor
optim
open
way
recent
discoveri
new
famili
cyclic
pem
novel
type
antimicrobi
activ
famili
repres
cyclic
peptid
figur
show
antimicrobi
activ
nanomolar
rang
specif
gramneg
pseudomona
sp
lead
compound
caus
lysi
bacteri
cell
membran
one
enantiom
molecul
antimicrobi
activ
mic
pseudomona
aeruginosa
enantiomer
form
essenti
inact
mic
amino
acid
sequenc
unrel
known
natur
occur
cap
although
like
cap
contain
mix
hydrophob
aromat
cation
residu
given
potent
antimicrobi
activ
import
human
pathogen
p
aeruginosa
like
novel
mechan
action
effort
made
develop
lead
clinic
develop
relat
molecul
call
muchimprov
stabil
toward
proteolysi
human
plasma
due
replac
multipl
lysarg
residu
diaminobutyr
acid
residu
substitut
larg
effect
antimicrobi
activ
remov
cleavag
site
trypsinlik
proteas
anoth
lead
call
optim
absorpt
distribut
metabol
elimin
toxic
properti
recent
complet
success
human
phase
clinic
trial
new
narrowspectrum
antibiot
target
p
aeruginosa
would
welcom
addit
rang
antibiot
current
avail
treat
seriou
hospitalacquir
infect
lifethreaten
difficulttotreat
drugresist
strain
aris
increas
frequenc
hospit
wider
commun
first
indic
like
mechan
action
came
photoaffin
label
experi
photoprob
figur
forward
genet
screen
resist
determin
p
aeruginosa
approach
identifi
om
protein
lptd
like
target
protein
om
gramneg
bacteria
contain
domain
embed
lipid
bilay
contrast
transmembran
protein
locat
inner
membran
im
typic
contain
segment
wherea
transmembran
helic
domain
commonli
found
human
membran
protein
eg
g
proteincoupl
receptor
domain
occur
surfac
human
cell
although
found
mitochondri
membran
mani
crystal
structur
protein
known
exampl
ompx
protein
e
coli
eightstrand
wherea
e
coli
porin
ompf
form
trimer
e
coli
om
lptd
much
larger
predict
contain
ctermin
domain
possibl
contain
ntermin
domain
unknown
structur
sit
periplasm
side
membran
past
year
much
learnt
function
lptd
e
coli
relat
gramneg
bacteria
review
lptd
exist
complex
lipid
protein
lpte
om
gramneg
bacteria
function
final
step
lipopolysaccharid
lp
transloc
cell
surfac
im
gramneg
bacteria
lipid
bilay
compos
phospholipid
wherea
om
asymmetr
bilay
compos
phospholipid
inner
leaflet
lp
outer
leaflet
figur
dival
ion
crosslink
phosphat
group
lp
molecul
strengthen
consider
om
render
highli
imperm
small
molecul
includ
antibiot
lp
contain
hydrophob
lipid
moieti
compris
five
seven
fatti
acid
chain
connect
disaccharid
compos
nacetylglucosamin
lipid
attach
typic
octasaccharid
carbohydr
core
turn
often
link
highli
immunogen
oantigen
oligosaccharid
lp
molecul
transport
across
two
membran
interven
periplasm
start
unravel
seven
essenti
lp
transport
lpt
protein
known
mediat
transport
process
heteromer
abc
transport
lptbfg
form
complex
im
togeth
membran
protein
lptc
figur
lptc
interact
periplasm
protein
lpta
headtotail
oligomer
form
like
creat
bridg
across
periplasm
lpta
bridg
make
contact
ntermin
periplasm
domain
lptd
om
transenvelop
protein
bridg
provid
highway
across
lp
molecul
shuttl
im
om
atpdepend
process
lumen
ctermin
domain
lptd
appear
least
partial
occupi
lpte
lptde
complex
accept
lp
molecul
lpta
periplasm
subsequ
transloc
unknown
mechan
outer
leaflet
upon
exposur
larg
accumul
membranelik
materi
seen
transmiss
electron
microscopi
associ
om
within
p
aeruginosa
cell
similar
accumul
membranelik
materi
seen
e
coli
lptd
essenti
gene
lpt
pathway
downregul
like
accumul
lp
molecul
im
photolabel
experi
demonstr
antibiot
bind
lptd
photoprob
figur
contain
photolabil
amino
acid
lphotoprolin
well
biotinyl
glu
residu
posit
hairpin
photoprob
still
potent
antibiot
mic
p
aeruginosa
despit
presenc
biotinyl
side
chain
uv
irradi
cell
expos
select
photolabel
lptd
protein
could
detect
membran
protein
extract
recent
studi
provid
evid
inhibit
lp
transport
om
p
aeruginosa
particular
elicit
chang
lp
structur
membran
morpholog
wildtyp
p
aeruginosa
cell
ident
seen
cell
condit
mutant
lptd
gene
downregul
result
obtain
consist
restrict
lp
transloc
om
caus
either
inhibit
downregul
lptd
accumul
im
recent
fold
pathway
nativ
lptd
e
coli
om
studi
detail
lpte
requir
lptd
fold
correctli
e
coli
domain
fold
om
process
catalyz
bam
machineri
conserv
complex
protein
respons
fold
insert
protein
om
gramneg
bacteria
ratedetermin
step
lptde
assembl
appear
fold
remark
slow
min
correspond
one
third
cell
cycl
fold
intermedi
form
lptd
substrat
periplasm
oxidas
dsba
catalyz
format
two
nonconsecut
intramolecular
disulfid
bond
e
coli
lptd
contain
four
cy
residu
two
periplasm
domain
residu
two
domain
residu
interestingli
cy
residu
correspond
conserv
gramneg
lptd
protein
includ
p
aeruginosa
lptd
p
aeruginosa
strain
larger
residu
e
coli
much
differ
aris
insert
within
ntermin
periplasm
domain
figur
cystein
correspond
found
e
coli
lptd
present
p
aeruginosa
lptd
howev
two
addit
cystein
present
p
aeruginosa
lptd
flank
insert
within
periplasm
domain
although
lptd
requir
gramneg
bacteria
biogenesi
om
clear
differ
size
sequenc
protein
occur
differ
microorgan
differ
may
account
unusu
select
antibiot
pseudomona
sp
far
report
cap
interact
om
protein
lipoprotein
bacteria
anoth
exampl
recent
report
bind
cap
lipoprotein
opri
p
aeruginosa
tantal
prospect
howev
cap
mimet
might
found
target
exampl
lptd
import
membran
protein
gramneg
human
pathogen
vaccin
develop
began
centuri
use
whole
microorgan
gener
protect
immun
respons
human
howev
live
attenu
inactiv
whole
viral
bacteri
vaccin
still
belong
success
human
vaccin
use
today
eg
oral
polio
measl
standalon
measlesmumpsrubella
combin
influenza
typhoid
cholera
bacillu
although
recur
problem
associ
product
contamin
genet
instabl
residu
virul
although
earli
vaccin
base
upon
protein
subunit
toxin
could
extract
bacteri
cell
eg
diphtheria
tetanu
flu
anthrax
rabi
emerg
tool
molecular
biolog
signal
new
era
vaccin
develop
stimul
protect
antibodi
respons
still
key
success
almost
prevent
vaccin
use
today
rather
use
whole
microorgan
vaccin
identifi
produc
individu
molecular
target
protect
antibodi
surfac
protein
polysaccharid
capsul
becam
import
focu
vaccin
research
challeng
problem
identifi
suitabl
surfac
antigen
bacteri
pathogen
abl
confer
protect
approach
recent
appli
largescal
genom
proteom
technolog
put
surfac
protein
bacteria
identifi
bioinformat
produc
recombin
protein
test
immunolog
highthroughput
fashion
abil
elicit
protect
immun
respons
empir
approach
term
revers
vaccinolog
success
approach
identifi
protect
antigen
demonstr
even
case
convent
approach
vaccin
develop
fail
howev
use
recombin
protein
vaccin
continu
reli
coadministr
suitabl
adjuv
provid
suffici
boost
immun
system
remain
problemat
adjuv
toxic
past
year
advanc
structur
biolog
led
dramat
increas
structur
knowledg
antibodi
recogn
vaccin
antigen
crystal
structur
pathogenderiv
antigen
bound
cognat
protect
antibodi
reveal
fold
antigen
conform
protect
humor
immun
respons
elicit
rais
prospect
new
era
ration
vaccin
develop
call
structur
vaccinolog
structur
inform
use
ration
design
novel
improv
vaccin
antigen
sever
recent
exampl
document
approach
lead
develop
new
viral
bacteri
vaccin
candid
implic
approach
could
substanti
given
mani
pathogen
vaccin
present
exist
eg
malaria
hepat
c
staphylococcu
aureu
well
prospect
novel
immunotherapeut
approach
might
develop
treat
chronic
human
diseas
cancer
recent
publish
crystal
structur
protect
monoclon
antibodi
mab
fragment
bound
protect
epitop
list
tabl
exampl
repres
epitop
viral
protein
largest
number
mani
case
new
biolog
method
exploit
isol
neutral
antibodi
human
sourc
eg
human
memori
bcell
immort
virus
typic
display
protein
surfac
facilit
identif
suitabl
antigen
protect
epitop
structur
knowledg
epitop
recogn
protect
antibodi
use
vaccin
design
one
approach
involv
epitop
graft
use
tool
protein
engin
epitop
interest
transfer
onto
new
protein
scaffold
perhap
stabl
easier
produc
immunogen
display
epitop
correctli
fold
conform
sever
recent
exampl
document
structurebas
method
model
allow
predict
protein
might
use
scaffold
newli
graft
epitop
case
howev
might
still
technic
difficult
produc
correctli
fold
protein
subunit
vaccin
moreov
nonprotect
epitop
surfac
recombin
protein
may
still
domin
immun
respons
therebi
deflect
attent
away
protect
epitop
lead
poorli
effect
vaccin
also
coadministr
adjuv
requir
boost
immunogen
altern
approach
exploit
advanc
synthet
peptid
protein
engin
use
tool
organ
peptid
chemistri
product
fold
protein
relat
epitop
mimet
conform
flexibl
one
key
paramet
must
address
design
synthet
epitop
mimet
use
flexibl
peptid
immunogen
often
elicit
antibodi
bind
weakli
kd
conform
epitop
fold
protein
howev
antibodi
bind
tightli
kd
antigen
usual
requir
protect
infect
effici
product
immun
respons
requir
use
correctli
fold
epitop
mimet
mani
protect
epitop
shown
tabl
contain
loop
motif
conform
constrain
synthet
epitop
mimet
base
structur
may
use
immunogen
vaccin
design
exampl
number
differ
technolog
stabil
helic
conform
peptid
develop
review
helic
conform
stabil
insert
amino
acid
restrict
conform
space
amino
acid
eg
aib
sidechain
crosslink
stapl
use
helix
cap
hydrogenbond
surrog
approach
explor
alreadi
vaccin
design
effort
exampl
use
aib
residu
favor
helic
turn
hydrazon
crosslink
hydrogen
bond
surrog
freidingerlik
lactam
pseudoprolin
stabil
turn
crosslink
stapl
side
chain
stabil
helic
epitop
seem
like
technolog
continu
refin
appli
larger
synthet
protein
glycoprotein
scaffold
mimet
might
also
use
synthet
vaccin
design
tabl
exampl
loop
highli
immunogen
region
envelop
glycoprotein
becom
expos
viral
surfac
receptor
target
cell
bind
viral
glycoprotein
figur
tip
loop
abl
dock
cellular
chemokin
coreceptor
ultim
lead
viru
entri
cell
mani
crystal
structur
avail
neutral
antibodi
fragment
bound
peptid
deriv
loop
tabl
loop
focu
mani
earlier
studi
epitop
mimet
design
linear
peptid
flexibl
solut
adopt
fold
structur
strategi
use
far
loop
mimet
design
includ
macrocycl
linear
peptid
introduct
nonnatur
amino
acid
stabil
turn
conform
introduct
one
crossstrand
disulfid
bridg
stabil
loop
conform
loop
mimet
also
design
transplant
loop
sequenc
onto
hairpinstabil
dpro
lpro
templat
discuss
earlier
dpro
lpro
templat
serv
stabil
conform
fix
hairpin
regist
amino
acid
hb
nhb
posit
crystal
structur
peptid
bound
mab
reveal
loop
conform
differ
hairpin
regist
mab
side
chain
point
side
hairpin
occupi
hb
posit
wherea
mab
hb
pair
complex
pair
hb
posit
four
mimet
call
iy
hf
hy
figur
design
transplant
loop
hb
pair
directli
attach
dpro
lpro
templat
studi
reveal
mimet
extens
network
longrang
noe
backbon
proton
crossstrand
residu
pair
well
side
chain
residu
locat
face
hairpin
leav
doubt
structur
highli
popul
adopt
expect
hairpin
regist
synthet
epitop
mimet
describ
earlier
expect
immunogen
requir
appropri
method
deliveri
immun
system
tradit
approach
taken
gener
immun
respons
weakli
immunogen
peptid
small
molecul
eg
hapten
involv
coupl
carrier
protein
keyhol
limpet
hemocyanin
administr
subcutan
inject
togeth
immunostimulatori
adjuv
often
effect
upon
peptid
protein
structur
conjug
process
administr
either
oilinwaterbas
particul
eg
alum
adjuv
unknown
problem
antigen
deliveri
long
recogn
fortun
address
result
progress
made
recent
decad
understand
cellular
molecular
level
mechan
immun
system
activ
immun
system
activ
effici
virus
bacteria
incorpor
key
signal
initi
immun
respons
thu
virus
bacteria
display
repetit
close
space
array
epitop
across
surfac
arrang
epitop
specif
recogn
foreign
b
cell
multipl
copi
epitop
pathogen
may
engag
multipl
bcell
receptor
bcr
individu
b
cell
crosslink
multipl
bcr
cell
surfac
gener
power
signal
initi
process
bcell
activ
matur
addit
protein
virus
bacteria
contain
peptid
sequenc
function
tcell
epitop
activ
tcell
arm
immun
system
includ
cell
provid
crucial
help
b
cell
cell
requir
cellmedi
immun
furthermor
virus
typic
sphere
ideal
size
shape
traffick
lymphat
system
mani
lymph
node
human
bodi
present
b
cell
follicular
dendrit
cell
dc
circul
b
lymphocyt
halt
lymph
node
encount
antigen
antigenpres
cell
apc
drain
interstiti
fluid
peripher
tissu
intact
antigen
present
b
cell
whereupon
epitop
bcr
recognit
occur
apc
present
tcell
epitop
linear
peptid
bound
major
histocompat
complex
molecul
recognit
tcell
receptor
cell
b
cell
becom
activ
danc
final
lead
product
antibodi
molecul
optim
bind
antigen
final
virus
bacteria
contain
molecul
uniqu
call
pathogenassoci
molecular
pattern
innat
immun
system
recogn
foreign
use
pattern
recognit
receptor
tolllik
receptor
pathogen
interact
directli
sever
type
human
immunocyt
contain
pattern
recognit
receptor
includ
monocyt
macrophag
myeloid
plasmacytoid
dc
interact
induc
variou
innat
immun
respons
includ
product
proinflammatori
cytokin
well
lead
matur
migrat
dc
lymph
node
therebi
promot
adapt
immun
respons
one
promis
approach
vaccin
deliveri
exploit
potent
immunostimulatori
properti
viruslik
particl
vlp
relat
artifici
nanoparticl
vlp
may
integr
key
immun
stimulatori
signal
one
nanos
particl
result
potent
immunolog
activ
vlp
typic
made
viral
capsid
protein
selfassembl
particul
structur
diamet
close
resembl
natur
virus
deriv
lack
genet
materi
noninfecti
replic
incompet
exampl
vlpbase
vaccin
current
use
hepat
b
vaccin
made
surfac
antigen
human
papillomaviru
vaccin
cervarix
gardasil
made
surfac
protein
spontan
form
vlp
solut
hepat
b
vaccin
made
surfac
antigen
also
first
wide
use
recombin
protein
vaccin
invent
mani
vlpbase
system
develop
use
carrier
vaccin
research
develop
one
idea
engin
capsid
protein
protect
foreign
epitop
insert
display
surfac
particl
cours
suitabl
site
capsid
protein
must
identifi
foreign
domain
contain
protect
epitop
insert
display
vlp
surfac
insert
domain
must
fold
correctli
engin
capsid
protein
must
still
abl
selfassembl
vlp
alway
easi
predict
altern
chemic
coupl
approach
taken
conjug
epitop
vlp
apart
biotechnolog
vlp
howev
also
great
interest
chemic
approach
vlplike
nanoparticl
use
vaccin
carrier
one
chemic
approach
report
recent
exploit
uniqu
chemic
physic
properti
design
synthet
lipopeptid
build
block
aqueou
buffer
spontan
selfassembl
homogen
nanoparticl
size
rang
call
synthet
vlp
svlp
figur
lipopeptid
build
block
includ
coiledcoil
sequenc
capabl
form
parallel
trimer
helic
bundl
fuse
thelper
epitop
lipid
portion
typic
phospholipid
phosphatidylethanolamin
bacteri
tolllik
receptor
ligand
coupl
terminu
peptid
chain
synthet
protein
epitop
mimet
coupl
close
end
peptid
chain
selfassembl
svlp
occur
spontan
aqueou
solut
driven
format
trimer
helic
bundl
associ
multipl
bundl
micellelik
particl
lipid
chain
buri
core
nanoparticl
dimens
diamet
constitut
peptid
lipid
nanoparticl
resembl
natur
virus
svlp
produc
chemic
synthesi
svlp
present
dens
array
copi
epitop
mimet
surfac
nanoparticl
recent
studi
show
dc
bind
rapidli
svlp
intern
use
multipl
endocyt
rout
domin
caveolinindepend
lipid
raftmedi
macropinocytosi
process
occur
slowli
proteolyt
cleavag
lipopeptid
process
highli
effect
howev
evidenc
strong
immun
respons
induc
svlp
anim
without
need
extern
adjuv
epitop
mimet
link
svlp
site
specif
high
effici
use
varieti
coupl
chemistri
exampl
loop
mimet
coupl
svlp
use
uniqu
cy
residu
near
cterminu
lipopeptid
build
block
figur
comput
model
result
svlp
shown
figur
support
extens
biophys
data
illustr
dens
array
epitop
mimet
display
particl
surfac
highli
immunogen
anim
model
rabbit
high
titer
igg
antibodi
induc
includ
antibodi
bind
specif
recombin
elisa
activ
affin
purifi
mimet
igg
also
test
use
wholecel
luciferas
reportergen
assay
base
upon
singl
round
infect
molecularli
clone
envpseudotyp
virus
howev
experi
infect
laboratori
mn
strain
success
inhibit
igg
inhibit
seen
neutralizationinsensit
tier
strain
isol
hivinfect
human
unless
virus
first
engin
delet
loop
region
result
howev
agreement
recent
studi
show
loop
antibodi
often
fail
reach
target
intact
envelop
trimer
viral
surfac
activ
shield
loop
case
result
margin
neutral
activ
new
strategi
overcom
shield
andor
directli
target
protect
epitop
need
nevertheless
studi
illustr
one
approach
structurebas
ration
design
vaccin
candid
approach
structur
chemistri
base
allow
design
vaccin
candid
focu
immun
respons
select
protect
epitop
deliv
highli
immunogen
format
next
step
demonstr
function
protect
vaccin
made
use
approach
certainli
plenti
import
target
vaccin
research
await
attent
